Down regulation of CFTR expression and/or mutations that disrupt CFTR function have been reported in non-small-cell lung cancer (NSCLC) [33,86,126,127], glioblastoma [128], bladder cancer [34,35,36], esophageal cancer [129,130], pancreatic cancer [131,132,133], nasopharyngeal cancer [134], prostate cancer [94], and breast cancer [37,95]. This evidence concerns the gene CFTR and breast cancer.